Graves hyperthyroidism
Pro Research Analysisby 
Searched over 200M research papers for "graves hyperthyroidism"
Graves' Hyperthyroidism: An Overview
Introduction to Graves' Hyperthyroidism
Graves' disease (GD) is the most common cause of hyperthyroidism, an autoimmune disorder where the immune system mistakenly attacks the thyroid gland, leading to its overactivity. This condition is characterized by the production of autoantibodies that stimulate the thyroid-stimulating hormone receptor (TSHR), causing excessive thyroid hormone secretion and thyroid gland enlargement Morgan2010Kahaly2018.
Pathophysiology and Genetic Factors
The pathophysiology of Graves' hyperthyroidism involves the interaction of TSHR autoantibodies with the thyroid gland, leading to unregulated thyroid hormone production. Additionally, these autoantibodies can cause extrathyroidal manifestations such as Graves' orbitopathy (GO) and pretibial myxedema, often through the synergistic action with insulin-like growth factor 1 receptor (IGF1R) . Genetic predisposition plays a significant role, accounting for approximately 79% of the risk, with environmental factors contributing the remaining 21% .
Clinical Manifestations
Graves' hyperthyroidism presents with a variety of symptoms including goitre, ophthalmopathy, and psychiatric manifestations such as mood and anxiety disorders. The hyperactivity of the adrenergic nervous system is believed to contribute to these psychiatric symptoms . GO, an orbital autoimmune disorder, affects about 30% of patients with GD and can range from mild to severe forms requiring immunosuppressive treatments .
Diagnosis
Diagnosis of Graves' hyperthyroidism is typically straightforward in patients with biochemically confirmed thyrotoxicosis, positive TSHR antibodies, and characteristic thyroid ultrasound findings. Measurement of TSHR antibodies is crucial for accurate diagnosis, especially in differentiating GD from other causes of hyperthyroidism .
Treatment Options
Antithyroid Drugs (ATD)
Antithyroid drugs such as methimazole (MMI) are commonly used to decrease thyroid hormone synthesis. MMI is preferred due to its efficacy and safety profile, with treatment courses typically lasting 12-18 months. In children, a longer course of 24-36 months is recommended . However, there is a high rate of recurrence after discontinuation of ATD Tørring1996Bartalena2013.
Radioiodine Therapy
Radioiodine (RAI) therapy is another treatment option that reduces thyroid tissue. It is contraindicated in patients with active or severe GO due to the risk of exacerbating the condition. Steroid prophylaxis is recommended for patients with mild active GO undergoing RAI therapy Kahaly2018Tørring1996.
Surgery
Total thyroidectomy is a definitive treatment option, especially for patients who relapse after ATD therapy. It should be performed by experienced surgeons to minimize risks such as hypoparathyroidism and laryngeal nerve damage Kahaly2018Tørring1996.
Special Considerations in Pregnancy
Managing Graves' hyperthyroidism during pregnancy requires careful monitoring and treatment adjustments to avoid maternal and fetal complications. Propylthiouracil is preferred during the first trimester, with a switch to MMI thereafter. Thyroid receptor antibodies should be assessed to predict and manage fetal or neonatal thyroid dysfunction .
Emerging Therapies
Recent advances in understanding the immunobiology of GD have led to the development of new therapeutic strategies, including biologics and small molecule peptides. Teprotumumab, an antibody targeting IGF-1R, has shown promise in treating GO. Additionally, components of traditional Chinese medicine are being explored for their potential benefits in managing Graves' hyperthyroidism .
Conclusion
Graves' hyperthyroidism is a complex autoimmune disorder with significant clinical and therapeutic challenges. While traditional treatments remain the mainstay, emerging therapies offer hope for more effective and targeted management. Ongoing research is essential to improve outcomes and quality of life for patients with this condition.
Sources and full results
Most relevant research papers on this topic
2018 European Thyroid Association Guideline for the Management of Graves’ Hyperthyroidism
Graves' hyperthyroidism is managed with antithyroid drugs, radioactive iodine, or thyroidectomy, with steroid prophylaxis recommended for patients with active orbitopathy.
Graves hyperthyroidism and pregnancy: a clinical update.
Preconception counseling and a multifaceted approach to care are crucial for a successful pregnancy in women with Graves hyperthyroidism.
DOI